News
AMPH
27.12
+1.16%
0.31
How My Seeking Alpha Stock Portfolio Crushed S&P 500
Seeking Alpha · 9h ago
Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?
NASDAQ · 2d ago
How Investors Are Reacting To Amphastar Pharmaceuticals (AMPH) Teriparatide Pen Approval And Insider Stock Sale
Simply Wall St · 3d ago
A Fresh Look at Amphastar Pharmaceuticals (AMPH) Valuation After Recent Share Price Stabilisation
Simply Wall St · 5d ago
Weekly Report: what happened at AMPH last week (1215-1219)?
Weekly Report · 6d ago
Can Amphastar’s Recent Rebound Signal a Compelling Opportunity in 2025?
Simply Wall St · 12/21 04:21
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO
NASDAQ · 12/20 05:44
Cheap smaller cap stocks that promise acceleration in fundamentals – BofA
Seeking Alpha · 12/19 16:57
Top Amphastar Executive Quietly Unloads a Significant Block of Shares
TipRanks · 12/19 02:04
Amphastar Pharmaceuticals Senior EVP Rong Zhou Reports Disposal of Common Shares
Reuters · 12/18 22:24
Wells Fargo Reaffirms Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
TipRanks · 12/18 16:15
Amphastar: Baqsimi Props Up Flat Growth, But 2026 Guidance Looks Fragile
Seeking Alpha · 12/16 12:30
Is FDA‑Cleared U.S.‑Made Teriparatide Pen Altering The Investment Case For Amphastar Pharmaceuticals (AMPH)?
Simply Wall St · 12/16 07:19
Amphastar Pharmaceuticals Director Makes Noteworthy Stock Sale
TipRanks · 12/16 02:03
Director Floyd F. Petersen Reports Disposal of Amphastar Pharmaceuticals Inc. Common Shares
Reuters · 12/15 22:18
Monday's ETF Movers: IHE, BLOK
NASDAQ · 12/15 20:06
Amphastar Pharmaceuticals Receives Buy Rating Following FDA Approval of AMP-015
TipRanks · 12/15 15:55
Amphastar reports FDA approval for teriparatide injection
Seeking Alpha · 12/15 11:33
Amphastar announces FDA approval for teriparatide injection
TipRanks · 12/15 11:11
Amphastar Announced FDA Approval for Teriparatide Injection
Benzinga · 12/15 11:05
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The Company manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The Company manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.